PaceMate announced today that it appointed Sean Shoffstall as its new head of AI, innovation and data strategy.
PaceMate offers an end-to-end platform for supporting the full spectrum of cardiac devices. That includes implantables, ambulatory monitors, heart failure devices and remote patient monitors. The company pairs this with a complete suite of solutions, including software, patient communications and clinical service support.
Just over a year ago, the company acquired Medtronic’s Paceart Optima cardiac workflow platform as well. Now, with the appointment of Shoffstall, the company hopes to drive its AI ambitions forward.
Shofstall joins with experience in senior roles at Beginly Health, Welby Health and Auditdata. At the latter, he played an integral part in the launch of the first HIPAA-compliant AI-generated audiogram analysis tool in the industry, according to a news release. Now, he aims to transform data-driven insights into automatic actions at PaceMate.
PaceMate now plans to introduce a number of AI and machine learning applications to its cardiac monitoring and workflow offerings. Shoffstall in his new post can drive forward an AI roadmap with an initial focus on three core areas. First, the company hopes to surface insights that matter most, then optimize clinics’ operational efficiency and care, then fuel medical and industry research.
Commentary from PaceMate officials
Recently appointed CEO JR Finkelmeier said:
“At PaceMate we’re dedicated to providing clinicians the software and services they need to provide the best patient care while overcoming legacy remote cardiac monitoring and operational roadblocks. Our natural next move is layering AI and machine learning capabilities on top of our data in a way that allows us to improve triage, enable population health, and even fuel preventive strategies. Shoffstall brings deep expertise in delivering such purpose-built solutions and is acutely aware of data sensitivities in the healthcare industry that can stand in the way of meeting regulatory requirements.”
Shoffstall added:
“The amount of data that PaceMate is sitting on to drive better outcomes is very exciting when viewed from an AI standpoint. And the remote cardiac monitoring space is overdue for AI applications that are regulated and safe for physicians to use in their daily workstreams. PaceMate has been producing clinic-level insights for years. With AI, we’ll now be able to give practitioners the option to act on some of them to automatically cut down their daunting workloads. And we’ll put historical and industry insights to work to progress healthcare at large. I’m honored to join PaceMate at this critical moment and look forward to working in tandem with the team and clients to define the next stage of remote cardiac monitoring.”
